{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:37:17Z","timestamp":1790869037509,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006162","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Ci\u00eancia e Tecnologia do Estado de Pernambuco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013166","name":"Fondation G\u00e9n\u00e9rale de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10787-023-01296-9","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T12:01:46Z","timestamp":1689940906000},"page":"433-446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["PPAR\u03b3 partial agonist LPSF\/GQ-16 prevents dermal and pulmonary fibrosis in HOCl-induced systemic sclerosis (SSc) and modulates cytokine production in PBMC of SSc patients"],"prefix":"10.1007","volume":"32","author":[{"given":"Anderson Rodrigues","family":"de Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a Tavares","family":"Dantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eduarda","family":"de Oliveira Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Ch\u00eane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Jeljeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Chouzenoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudes Gustavo Constantino","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian David","family":"de Azevedo Valadares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Victor","family":"de Melo Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sim\u00e3o Kalebe Silva","family":"de Paula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Galdino","family":"da Rocha Pitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"da Rocha Pitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moacyr Jesus Barreto","family":"de Melo R\u00eago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1672-8202","authenticated-orcid":false,"given":"Michelly Cristiny","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Luzia Branco Pinto","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulcineia Saes Parra","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Nicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Batteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maira Galdino","family":"da Rocha Pitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"1296_CR1","doi-asserted-by":"publisher","first-page":"15220","DOI":"10.1074\/jbc.275.20.15220","volume":"275","author":"DJ Abraham","year":"2000","unstructured":"Abraham DJ, Shiwen X, Black CM et al (2000) Tumor necrosis factor \u03b1 suppresses the induction of connective tissue growth factor by transforming growth factor-\u03b2 in normal and scleroderma fibroblasts. J Biol Chem 275:15220\u201315225. https:\/\/doi.org\/10.1074\/jbc.275.20.15220","journal-title":"J Biol Chem"},{"key":"1296_CR2","doi-asserted-by":"publisher","first-page":"28169","DOI":"10.1074\/jbc.M111.332106","volume":"287","author":"AA Amato","year":"2012","unstructured":"Amato AA, Rajagopalan S, Lin JZ et al (2012) GQ-16, a novel peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) ligand, promotes insulin sensitization without weight gain. J Biol Chem 287:28169\u201328179. https:\/\/doi.org\/10.1074\/jbc.M111.332106","journal-title":"J Biol Chem"},{"key":"1296_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3109\/03009742.2011.585349","volume":"40","author":"A Antonelli","year":"2011","unstructured":"Antonelli A, Ferri C, Ferrari SM et al (2011) IFN-\u03b3 and TNF-\u03b1 induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls. Scand J Rheumatol 40:453\u2013456. https:\/\/doi.org\/10.3109\/03009742.2011.585349","journal-title":"Scand J Rheumatol"},{"key":"1296_CR4","doi-asserted-by":"publisher","DOI":"10.1515\/rjim-2015-0006","author":"P B\u0103l\u0103nescu","year":"2015","unstructured":"B\u0103l\u0103nescu P, L\u0103daru A, B\u0103l\u0103nescu E et al (2015) IL-17, IL-6 and IFN-\u03b3 in systemic sclerosis patients. Rom J Intern Med. https:\/\/doi.org\/10.1515\/rjim-2015-0006","journal-title":"Rom J Intern Med"},{"key":"1296_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.autrev.2010.08.003","volume":"10","author":"J Baraut","year":"2010","unstructured":"Baraut J, Michel L, Verrecchia F, Farge D (2010) Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 10:65\u201373. https:\/\/doi.org\/10.1016\/j.autrev.2010.08.003","journal-title":"Autoimmun Rev"},{"issue":"Suppl 1","key":"1296_CR6","first-page":"3","volume":"37","author":"S Barsotti","year":"2019","unstructured":"Barsotti S, Orlandi M, Codullo V et al (2019) One year in review 2019: systemic sclerosis. Clin Exp Rheumatol 37(Suppl 1):3\u201314","journal-title":"Clin Exp Rheumatol"},{"key":"1296_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10010163","author":"D Benfaremo","year":"2022","unstructured":"Benfaremo D, Svegliati S, Paolini C et al (2022) Systemic sclerosis: from pathophysiology to novel therapeutic approaches. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10010163","journal-title":"Biomedicines"},{"key":"1296_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13238","author":"M Brown","year":"2018","unstructured":"Brown M, Reilly SO (2018) The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. https:\/\/doi.org\/10.1111\/cei.13238","journal-title":"Clin Exp Immunol"},{"key":"1296_CR9","doi-asserted-by":"publisher","first-page":"L1146","DOI":"10.1152\/ajplung.00383.2004","volume":"288","author":"HA Burgess","year":"2005","unstructured":"Burgess HA, Daugherty LE, Thatcher TH et al (2005) PPAR\u03b3 agonists inhibit TGF-\u03b2 induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Cell Mol Physiol 288:L1146\u2013L1153. https:\/\/doi.org\/10.1152\/ajplung.00383.2004","journal-title":"Am J Physiol Cell Mol Physiol"},{"key":"1296_CR10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1080\/09553002.2021.1987556","volume":"97","author":"MB Cavalcanti","year":"2021","unstructured":"Cavalcanti MB, L\u00facia L, Leite B et al (2021) Evaluation of the action of LPSF \/ GQ-16 on cytokines and PPAR- \u03b3 gene expression after in vitro irradiation of peripheral blood mononuclear cells. Int J Radiat Biol 97:1649\u20131656. https:\/\/doi.org\/10.1080\/09553002.2021.1987556","journal-title":"Int J Radiat Biol"},{"key":"1296_CR11","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1016\/j.bmc.2015.03.071","volume":"23","author":"N Chadha","year":"2015","unstructured":"Chadha N, Bahia MS, Kaur M, Silakari O (2015) Thiazolidine-2,4-dione derivatives: Programmed chemical weapons for key protein targets of various pathological conditions. Bioorganic Med Chem 23:2953\u20132974. https:\/\/doi.org\/10.1016\/j.bmc.2015.03.071","journal-title":"Bioorganic Med Chem"},{"key":"1296_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154310","volume":"11","author":"MS Coelho","year":"2016","unstructured":"Coelho MS, de Lima CL, Royer C et al (2016) GQ-16, a TZD-derived partial PPAR\u03b3 agonist, induces the expression of thermogenesis-related genes in brown fat and visceral white fat and decreases visceral adiposity in obese and hyperglycemic mice. PLoS ONE 11:e0154310","journal-title":"PLoS ONE"},{"issue":"18","key":"1296_CR13","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.3390\/ijms20184337","volume":"20","author":"M Colletti","year":"2019","unstructured":"Colletti M, Galardi A, De Santis M, Guidelli GM, Di Giannatale A, Di Luigi L, Antinozzi C (2019) Exosomes in systemic sclerosis: messengers between immune, vascular and fibrotic components? Int J Mol Sci 20(18):4337. https:\/\/doi.org\/10.3390\/ijms20184337","journal-title":"Int J Mol Sci"},{"key":"1296_CR14","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1191\/0961203305lu2223oa","volume":"14","author":"A Consoli","year":"2005","unstructured":"Consoli A, Devangelio E (2005) Thiazolidinediones and inflammation. Lupus 14:794\u2013797. https:\/\/doi.org\/10.1191\/0961203305lu2223oa","journal-title":"Lupus"},{"key":"1296_CR15","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.ejmech.2007.02.015","volume":"42","author":"LFC da Costa Leite","year":"2007","unstructured":"da Costa Leite LFC, Veras Mour\u00e3o RH, de Lima M, do CA, et al (2007) Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities. Eur J Med Chem 42:1263\u20131271. https:\/\/doi.org\/10.1016\/j.ejmech.2007.02.015","journal-title":"Eur J Med Chem"},{"key":"1296_CR16","doi-asserted-by":"publisher","unstructured":"Dantas AT, Pereira MC, de Melo Rego MJB, et al (2015) The Role of PPAR Gamma in Systemic Sclerosis. PPAR Res 2015:124624. https:\/\/doi.org\/10.1155\/2015\/124624","DOI":"10.1155\/2015\/124624"},{"key":"1296_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-019-00600-w","author":"AR de Almeida","year":"2019","unstructured":"de Almeida AR, Dantas AT, Pereira MC et al (2019) Dexamethasone inhibits cytokine production in PBMC from systemic sclerosis patients. Inflammopharmacology. https:\/\/doi.org\/10.1007\/s10787-019-00600-w","journal-title":"Inflammopharmacology"},{"key":"1296_CR18","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Supplemental - Systemic sclerosis. Lancet 390:1685\u20131699. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9","journal-title":"Lancet"},{"key":"1296_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1357-2725(96)00112-4","volume":"29","author":"A Diaz","year":"1997","unstructured":"Diaz A, Jim\u00e9nez SA (1997) Interferon-gamma regulates collagen and fibronectin gene expression by transcriptional and post-transcriptional mechanisms. Int J Biochem Cell Biol 29:251\u2013260. https:\/\/doi.org\/10.1016\/S1357-2725(96)00112-4","journal-title":"Int J Biochem Cell Biol"},{"issue":"2 Suppl 65","key":"1296_CR20","first-page":"S40","volume":"29","author":"JH Distler","year":"2011","unstructured":"Distler JH, Jordan S, Airo P, Alegre-Sancho JJ, Allanore Y, Balbir Gurman A, Caporali R, Caramaschi P, Carreira PE, Chizzolini C, Cutolo M, Tuncay Duru\u00f6z M, Farge-Bancel D, Hesselstrand R, Iannone F, De Keyser F, Kucharz EJ, Launay D, de la Pe\u00f1a Garc\u00eda, Lefebvre P, Lukacova O, Marasini B, Martinovic D, Marques Neto JF, Radic M, Rednic S, Riemekasten G, Rovensky J, Seidel MF, Senel S, Smith V, Sunderk\u00f6tter C, Ton E, van Laar JM, Matucci-Cerinic M, M\u00fcller Ladner U, Distler O (2011) Is there a role for TNF\u03b1 antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol 29(2 Suppl 65):S40-5","journal-title":"Clin Exp Rheumatol"},{"key":"1296_CR21","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.2174\/092986711796504600","volume":"18","author":"AL Faine","year":"2011","unstructured":"Faine AL, Rudnicki M, Cesar AF et al (2011) Anti-inflammatory and antioxidant properties of a new arylidene-thiazolidinedione in macrophages. Curr Med Chem 18:3351\u20133360. https:\/\/doi.org\/10.2174\/092986711796504600","journal-title":"Curr Med Chem"},{"key":"1296_CR22","doi-asserted-by":"publisher","unstructured":"Fuschiotti P (2018) O PINION T cells and cytokines in systemic sclerosis. 30:594\u2013599. https:\/\/doi.org\/10.1097\/BOR.0000000000000553","DOI":"10.1097\/BOR.0000000000000553"},{"key":"1296_CR23","doi-asserted-by":"publisher","first-page":"154799","DOI":"10.1016\/j.cyto.2019.154799","volume":"125","author":"G Gasparini","year":"2020","unstructured":"Gasparini G, Cozzani E, Parodi A (2020) Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis. Cytokine 125:154799. https:\/\/doi.org\/10.1016\/j.cyto.2019.154799","journal-title":"Cytokine"},{"key":"1296_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08916934.2017.1416467","volume":"51","author":"RSG Gon\u00e7alves","year":"2018","unstructured":"Gon\u00e7alves RSG, Pereira MC, Dantas AT et al (2018) IL-17 and related cytokines involved in systemic sclerosis: Perspectives. Autoimmunity 51:1\u20139. https:\/\/doi.org\/10.1080\/08916934.2017.1416467","journal-title":"Autoimmunity"},{"key":"1296_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-01844-y","volume":"16","author":"E Hachulla","year":"2021","unstructured":"Hachulla E, Agard C, Allanore Y et al (2021) French recommendations for the management of systemic sclerosis. Orphanet J Rare Dis 16:1\u201361. https:\/\/doi.org\/10.1186\/s13023-021-01844-y","journal-title":"Orphanet J Rare Dis"},{"key":"1296_CR26","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/1521-4141(200104)31:4<1098::AID-IMMU1098>3.0.CO;2-I","volume":"31","author":"SG Harris","year":"2001","unstructured":"Harris SG, Phipps RP (2001) The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. Eur J Immunol 31:1098\u20131105. https:\/\/doi.org\/10.1002\/1521-4141(200104)31:4%3c1098::AID-IMMU1098%3e3.0.CO;2-I","journal-title":"Eur J Immunol"},{"key":"1296_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1600-0625.2008.00828.x","volume":"18","author":"N Higashi-Kuwata","year":"2009","unstructured":"Higashi-Kuwata N, Makino T, Inoue Y et al (2009) Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp Dermatol 18:727\u2013729","journal-title":"Exp Dermatol"},{"key":"1296_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-020-00918-3","author":"M Hinchcliff","year":"2020","unstructured":"Hinchcliff M, O\u2019Reilly S (2020) Current and potential new targets in systemic sclerosis therapy: a new hope. Curr Rheumatol Rep. https:\/\/doi.org\/10.1007\/s11926-020-00918-3","journal-title":"Curr Rheumatol Rep"},{"key":"1296_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/art.37738","volume":"65","author":"T H\u00fcgle","year":"2013","unstructured":"H\u00fcgle T, O\u2019Reilly S, Simpson R et al (2013) Tumor necrosis factor-costimulated T lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthritis Rheum 65:481\u2013491. https:\/\/doi.org\/10.1002\/art.37738","journal-title":"Arthritis Rheum"},{"key":"1296_CR30","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/archderm.133.5.609","volume":"133","author":"N Hunzelmann","year":"1997","unstructured":"Hunzelmann N, Anders S, Fierlbeck G et al (1997) Systemic scleroderma. Multicenter trial of 1 year of treatment with recombinant interferon gamma. Arch Dermatol 133:609\u2013613. https:\/\/doi.org\/10.1001\/archderm.133.5.609","journal-title":"Arch Dermatol"},{"issue":"7","key":"1296_CR31","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/j.bmc.2013.01.029","volume":"21","author":"VS Jain","year":"2013","unstructured":"Jain VS, Vora DK, Ramaa CS (2013) Thiazolidine-2,4-diones: progress towards multifarious applications. Bioorg Med Chem 21(7):1599\u2013620. https:\/\/doi.org\/10.1016\/j.bmc.2013.01.029","journal-title":"Bioorg Med Chem"},{"key":"1296_CR33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0002-9343(89)80150-0","volume":"87","author":"A Kahan","year":"1989","unstructured":"Kahan A, Amor B, Menkes CJ, Strauch G (1989) Recombinant interferon-gamma in the treatment of systemic sclerosis. Am J Med 87:273\u2013277. https:\/\/doi.org\/10.1016\/s0002-9343(89)80150-0","journal-title":"Am J Med"},{"key":"1296_CR34","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/ard.2004.027094","volume":"64","author":"A Kalogerou","year":"2005","unstructured":"Kalogerou A, Gelou E, Mountantonakis S et al (2005) Early T cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 64:1233\u20131235. https:\/\/doi.org\/10.1136\/ard.2004.027094","journal-title":"Ann Rheum Dis"},{"key":"1296_CR35","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1002\/art.34534","volume":"64","author":"N Kavian","year":"2012","unstructured":"Kavian N, Marut W, Servettaz A et al (2012) Reactive oxygen species-mediated killing of activated fibroblasts by arsenic trioxide ameliorates fibrosis in a murine model of systemic sclerosis. Arthritis Rheum 64:3430\u20133440. https:\/\/doi.org\/10.1002\/art.34534","journal-title":"Arthritis Rheum"},{"key":"1296_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/labinvest.2008.104","volume":"89","author":"T Kawai","year":"2009","unstructured":"Kawai T, Masaki T, Doi S et al (2009) PPAR-g agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF- b. Lab Investig 89:47\u201358. https:\/\/doi.org\/10.1038\/labinvest.2008.104","journal-title":"Lab Investig"},{"key":"1296_CR37","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1002\/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K","volume":"43","author":"K Kurasawa","year":"2000","unstructured":"Kurasawa K, Hirose K, Sano H et al (2000) Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 43:2455\u20132463. https:\/\/doi.org\/10.1002\/1529-0131(200011)43:11%3c2455::AID-ANR12%3e3.0.CO;2-K","journal-title":"Arthritis Rheum"},{"key":"1296_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01702","author":"P Laurent","year":"2018","unstructured":"Laurent P, Sisirak V, Lazaro E et al (2018) Innate immunity in systemic sclerosis fibrosis: recent advances. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.01702","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"1296_CR39","first-page":"14","volume":"34","author":"L Lei","year":"2016","unstructured":"Lei L, Zhao C, Qin F et al (2016) Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis. Clin Exp Rheumatol 34(Suppl 1):14\u201322","journal-title":"Clin Exp Rheumatol"},{"key":"1296_CR40","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy EC, Medsger J (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573\u20131576","journal-title":"J Rheumatol"},{"key":"1296_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/13543784.2021.1923693","volume":"30","author":"A Lescoat","year":"2021","unstructured":"Lescoat A, Varga J, Matucci-Cerinic M, Khanna D (2021) New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. Expert Opin Investig Drugs 30:635\u2013652. https:\/\/doi.org\/10.1080\/13543784.2021.1923693","journal-title":"Expert Opin Investig Drugs"},{"key":"1296_CR42","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s12010-022-04190-2","volume":"195","author":"Y Li","year":"2023","unstructured":"Li Y, Ks N, Byran G, Krishnamurthy PT (2023) Identification of selective PPAR-\u03b3 modulators by combining pharmacophore modeling, molecular docking, and adipogenesis assay. Appl Biochem Biotechnol 195:1014\u20131041. https:\/\/doi.org\/10.1007\/s12010-022-04190-2","journal-title":"Appl Biochem Biotechnol"},{"key":"1296_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.02571","volume":"9","author":"ATJ Maria","year":"2018","unstructured":"Maria ATJ, Toupet K, Maumus M et al (2018) Fibrosis development in HOCl-induced systemic sclerosis: a multistage process hampered by mesenchymal stem cells. Front Immunol 9:1\u201313. https:\/\/doi.org\/10.3389\/fimmu.2018.02571","journal-title":"Front Immunol"},{"key":"1296_CR44","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"AT Masi","year":"1980","unstructured":"Masi AT (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581\u2013590. https:\/\/doi.org\/10.1002\/art.1780230510","journal-title":"Arthritis Rheum"},{"key":"1296_CR45","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/annrheumdis-2011-200709","volume":"71","author":"ACK MathianParizotDorgham","year":"2012","unstructured":"MathianParizotDorgham ACK et al (2012) Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 71:1227\u20131234. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200709","journal-title":"Ann Rheum Dis"},{"key":"1296_CR46","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1080\/14656566.2020.1793960","volume":"21","author":"ZH McMahan","year":"2020","unstructured":"McMahan ZH, Volkmann ER (2020) An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. Expert Opin Pharmacother 21:2041\u20132056. https:\/\/doi.org\/10.1080\/14656566.2020.1793960","journal-title":"Expert Opin Pharmacother"},{"key":"1296_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01861","volume":"10","author":"M Meng","year":"2019","unstructured":"Meng M, Tan J, Chen W et al (2019) The fibrosis and immunological features of hypochlorous acid induced mouse model of systemic sclerosis. Front Immunol 10:1\u201310. https:\/\/doi.org\/10.3389\/fimmu.2019.01861","journal-title":"Front Immunol"},{"key":"1296_CR48","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1152\/ajplung.00333.2007","volume":"294","author":"JE Milam","year":"2008","unstructured":"Milam JE, Keshamouni VG, Phan SH et al (2008) PPAR-\u03b3 agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294:891\u2013901. https:\/\/doi.org\/10.1152\/ajplung.00333.2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1296_CR49","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.bbrc.2015.07.011","volume":"464","author":"FA Milton","year":"2015","unstructured":"Milton FA, Cvoro A, Amato AA et al (2015) PPAR\u03b3 partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes. Biochem Biophys Res Commun 464:718\u2013723. https:\/\/doi.org\/10.1016\/j.bbrc.2015.07.011","journal-title":"Biochem Biophys Res Commun"},{"key":"1296_CR50","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.ejmech.2005.06.002","volume":"40","author":"RH Mour\u00e3o","year":"2005","unstructured":"Mour\u00e3o RH, Silva TG, Soares ALM et al (2005) Synthesis and biological activity of novel acridinylidene and benzylidene thiazolidinediones. Eur J Med Chem 40:1129\u20131133. https:\/\/doi.org\/10.1016\/j.ejmech.2005.06.002","journal-title":"Eur J Med Chem"},{"key":"1296_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-019-1431-x","volume":"20","author":"\u00c1 N\u00e9meth","year":"2019","unstructured":"N\u00e9meth \u00c1, M\u00f3zes MM, Calvier L et al (2019) The PPAR\u03b3agonist pioglitazone prevents TGF-\u03b2 induced renal fibrosis by repressing EGR-1 and STAT3. BMC Nephrol 20:1\u20139. https:\/\/doi.org\/10.1186\/s12882-019-1431-x","journal-title":"BMC Nephrol"},{"key":"1296_CR52","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000164","volume":"11","author":"QM Nhu","year":"2020","unstructured":"Nhu QM, Hsieh L, Dohil L et al (2020) Antifibrotic effects of the thiazolidinediones in eosinophilic esophagitis pathologic remodeling: a preclinical evaluation. Clin Transl Gastroenterol 11:e00164. https:\/\/doi.org\/10.14309\/ctg.0000000000000164","journal-title":"Clin Transl Gastroenterol"},{"key":"1296_CR53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1586\/17469872.2.2.203","volume":"2","author":"TM Olski","year":"2007","unstructured":"Olski TM, Hunzelmann N (2007) Immunosuppressive and antifibrotic therapy of systemic sclerosis. Expert Rev Dermatol 2:203\u2013215. https:\/\/doi.org\/10.1586\/17469872.2.2.203","journal-title":"Expert Rev Dermatol"},{"issue":"2 Suppl 71","key":"1296_CR54","first-page":"S55","volume":"30","author":"MA Omair","year":"2012","unstructured":"Omair MA, Phumethum V, Johnson SR (2012) Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis. Clin Exp Rheumatol 30(2 Suppl 71):S55-9","journal-title":"Clin Exp Rheumatol"},{"key":"1296_CR55","doi-asserted-by":"publisher","first-page":"6941","DOI":"10.4049\/jimmunol.165.12.6941","volume":"165","author":"J Padilla","year":"2000","unstructured":"Padilla J, Kaur K, Cao HJ et al (2000) Peroxisome proliferator activator receptor-\u03b3 agonists and 15-deoxy-\u0394 12,14 12,14 -PGJ 2 induce apoptosis in normal and malignant B-lineage cells. J Immunol 165:6941\u20136948. https:\/\/doi.org\/10.4049\/jimmunol.165.12.6941","journal-title":"J Immunol"},{"key":"1296_CR56","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","volume":"6","author":"D Pattanaik","year":"2015","unstructured":"Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE (2015) Pathogenesis of systemic sclerosis. Front Immunol 6:272. https:\/\/doi.org\/10.3389\/fimmu.2015.00272","journal-title":"Pathogenesis of systemic sclerosis. Front Immunol"},{"key":"1296_CR57","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3899\/jrheum.100361","volume":"38","author":"V Phumethum","year":"2011","unstructured":"Phumethum V, Jamal S, Johnson SR (2011) Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol 38:289\u2013296. https:\/\/doi.org\/10.3899\/jrheum.100361","journal-title":"J Rheumatol"},{"key":"1296_CR58","doi-asserted-by":"crossref","unstructured":"Press D (2016) Hypoglycemic agents and potential anti-inflammatory activity, pp 27\u201338","DOI":"10.2147\/JIR.S86917"},{"key":"1296_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21197100","volume":"21","author":"C Rafael-Vidal","year":"2020","unstructured":"Rafael-Vidal C, P\u00e9rez N, Altab\u00e1s I et al (2020) Blocking il-17: A promising strategy in the treatment of systemic rheumatic diseases. Int J Mol Sci 21:1\u201314. https:\/\/doi.org\/10.3390\/ijms21197100","journal-title":"Int J Mol Sci"},{"key":"1296_CR60","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00281-015-0511-7","volume":"37","author":"J Raja","year":"2015","unstructured":"Raja J, Denton CP (2015) Cytokines in the immunopathology of systemic sclerosis. Semin Immunopathol 37:543\u2013557. https:\/\/doi.org\/10.1007\/s00281-015-0511-7","journal-title":"Semin Immunopathol"},{"key":"1296_CR61","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/34178","volume":"391","author":"M Ricote","year":"1998","unstructured":"Ricote M, Li AC, Willson TM et al (1998) The peroxisome proliferator-activated receptor-\u03b3 is a negative regulator of macrophage activation. Nature 391:79\u201382. https:\/\/doi.org\/10.1038\/34178","journal-title":"Nature"},{"key":"1296_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-021-00437-9","author":"YX She","year":"2021","unstructured":"She YX, Yu QY, Tang XX (2021) Role of interleukins in the pathogenesis of pulmonary fibrosis. Cell Death Discov. https:\/\/doi.org\/10.1038\/s41420-021-00437-9","journal-title":"Cell Death Discov"},{"key":"1296_CR63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.carpath.2012.05.006","volume":"22","author":"AK Soares E Silva","year":"2013","unstructured":"Soares E Silva AK, De Oliveira Cipriano Torres D, Santos Rocha SW et al (2013) Effect of new thiazolidine derivatives LPSF\/GQ-02 and LPSF\/GQ-16 on atherosclerotic lesions in LDL receptor-deficient mice (LDLR-\/-). Cardiovasc Pathol 22:81\u201390. https:\/\/doi.org\/10.1016\/j.carpath.2012.05.006","journal-title":"Cardiovasc Pathol"},{"key":"1296_CR64","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1136\/annrheumdis-2018-213648","volume":"77","author":"S Soldano","year":"2018","unstructured":"Soldano S, Trombetta AC, Contini P et al (2018) Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis. Ann Rheum Dis 77:1842\u20131845. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213648","journal-title":"Ann Rheum Dis"},{"key":"1296_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2015.00496","volume":"6","author":"L Soto","year":"2015","unstructured":"Soto L, Ferrier A, Aravena O et al (2015) Systemic sclerosis patients present alterations in the expression of molecules involved in B-cell regulation. Front Immunol 6:1\u20139. https:\/\/doi.org\/10.3389\/fimmu.2015.00496","journal-title":"Front Immunol"},{"key":"1296_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-017-0417-1","volume":"9","author":"JN Taroni","year":"2017","unstructured":"Taroni JN, Greene CS, Martyanov V et al (2017) A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med 9:1\u201324. https:\/\/doi.org\/10.1186\/s13073-017-0417-1","journal-title":"Genome Med"},{"key":"1296_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp103","author":"JE Toblli","year":"2009","unstructured":"Toblli JE, Ferrini MG, Cao G et al (2009) Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrology Dial Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfp103","journal-title":"Nephrology Dial Transplant"},{"key":"1296_CR68","doi-asserted-by":"publisher","first-page":"90579","DOI":"10.18632\/oncotarget.21234","volume":"8","author":"A Vall\u00e9e","year":"2017","unstructured":"Vall\u00e9e A, Lecarpentier Y, Guillevin R, Vall\u00e9e JN (2017) Interactions between TGF-\u03b21, canonical WNT\/\u03b2-catenin pathway and PPAR \u03b3 in radiation-induced fibrosis. Oncotarget 8:90579\u201390604. https:\/\/doi.org\/10.18632\/oncotarget.21234","journal-title":"Oncotarget"},{"key":"1296_CR69","doi-asserted-by":"publisher","first-page":"30226","DOI":"10.1074\/jbc.M005310200","volume":"275","author":"F Verrecchia","year":"2000","unstructured":"Verrecchia F, Pessah M, Atfi A, Mauviel A (2000) Tumor necrosis factor-\u03b1 inhibits transforming growth factor-\u03b2\/Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 275:30226\u201330231. https:\/\/doi.org\/10.1074\/jbc.M005310200","journal-title":"J Biol Chem"},{"key":"1296_CR70","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/ard.55.10.761","volume":"55","author":"PG Vlachoyiannopoulos","year":"1996","unstructured":"Vlachoyiannopoulos PG, Tsifetaki N, Dimitriou I et al (1996) Safety and efficacy of recombinant gamma interferon in the treatment of systemic sclerosis. Ann Rheum Dis 55:761\u2013768. https:\/\/doi.org\/10.1136\/ard.55.10.761","journal-title":"Ann Rheum Dis"},{"key":"1296_CR71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2397198320915042","volume":"6","author":"ER Volkmann","year":"2020","unstructured":"Volkmann ER, Fischer A (2020) Update on morbidity and mortality in systemic sclerosis\u2013related interstitial lung disease. J Scleroderma Relat Disord 6:11\u201320. https:\/\/doi.org\/10.1177\/2397198320915042","journal-title":"J Scleroderma Relat Disord"},{"key":"1296_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-019-1171-2","volume":"20","author":"TN Vu","year":"2019","unstructured":"Vu TN, Chen X, Foda HD et al (2019) Interferon-\u03b3enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation. Respir Res 20:1\u201314. https:\/\/doi.org\/10.1186\/s12931-019-1171-2","journal-title":"Respir Res"},{"key":"1296_CR73","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.phrs.2016.02.028","volume":"111","author":"S Wang","year":"2016","unstructured":"Wang S, Dougherty EJ, Danner RL (2016) PPAR\u03b3 signaling and emerging opportunities for improved therapeutics. Pharmacol Res 111:76\u201385. https:\/\/doi.org\/10.1016\/j.phrs.2016.02.028","journal-title":"Pharmacol Res"},{"key":"1296_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013778","volume":"5","author":"J Wei","year":"2010","unstructured":"Wei J, Ghosh AK, Sargent JL et al (2010) PPAR\u03b3 downregulation by TGF\u00df in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS ONE 5:e13778. https:\/\/doi.org\/10.1371\/journal.pone.0013778","journal-title":"PLoS ONE"},{"key":"1296_CR75","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/0003-9861(61)90291-0","volume":"93","author":"JF Woessner","year":"1961","unstructured":"Woessner JF (1961) The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 93:440\u2013447. https:\/\/doi.org\/10.1016\/0003-9861(61)90291-0","journal-title":"Arch Biochem Biophys"},{"key":"1296_CR76","doi-asserted-by":"publisher","first-page":"102526","DOI":"10.1016\/j.jaut.2020.102526","volume":"113","author":"JC Worrell","year":"2020","unstructured":"Worrell JC, O\u2019Reilly S (2020) Bi-directional communication: Conversations between fibroblasts and immune cells in systemic sclerosis. J Autoimmun 113:102526. https:\/\/doi.org\/10.1016\/j.jaut.2020.102526","journal-title":"J Autoimmun"},{"key":"1296_CR77","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2353\/ajpath.2009.080574","volume":"174","author":"M Wu","year":"2009","unstructured":"Wu M, Melichian DS, Chang E et al (2009) Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-\u03b2. Am J Pathol 174:519\u2013533. https:\/\/doi.org\/10.2353\/ajpath.2009.080574","journal-title":"Am J Pathol"},{"key":"1296_CR78","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1074\/jbc.275.7.4541","volume":"275","author":"XY Yang","year":"2000","unstructured":"Yang XY, Wang LH, Chen T et al (2000) Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) Agonists. J Biol Chem 275:4541\u20134544. https:\/\/doi.org\/10.1074\/jbc.275.7.4541","journal-title":"J Biol Chem"},{"key":"1296_CR79","doi-asserted-by":"publisher","first-page":"R4","DOI":"10.1186\/ar4430","volume":"16","author":"X Yang","year":"2014","unstructured":"Yang X, Yang J, Xing X et al (2014) Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther 16:R4. https:\/\/doi.org\/10.1186\/ar4430","journal-title":"Arthritis Res Ther"},{"key":"1296_CR80","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMra041001","volume":"351","author":"H Yki-J\u00e4rvinen","year":"2004","unstructured":"Yki-J\u00e4rvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106\u20131118. https:\/\/doi.org\/10.1056\/NEJMra041001","journal-title":"N Engl J Med"},{"key":"1296_CR81","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejcdt.2014.10.004","volume":"64","author":"M Yousif","year":"2015","unstructured":"Yousif M, Habib R, Esaely H et al (2015) Interleukin-6 in systemic sclerosis and potential correlation with pulmonary involvement. Egypt J Chest Dis Tuberc 64:237\u2013241. https:\/\/doi.org\/10.1016\/j.ejcdt.2014.10.004","journal-title":"Egypt J Chest Dis Tuberc"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-023-01296-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-023-01296-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-023-01296-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T06:14:44Z","timestamp":1709619284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-023-01296-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1296"],"URL":"https:\/\/doi.org\/10.1007\/s10787-023-01296-9","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"5 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study protocol with patients was revised and approved by the ethics committee in research involving humans of the Federal University of Pernambuco (CAAE 97393718.0.0000.5208). The animal study protocol was approved by the Comit\u00e9 d'Ethique en Mati\u00e8re d'Exp\u00e9rimentation Animale de Paris Descartes (CEEA 34) (Protocol number: APAFIS#26065-2019080816497351).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The present study included patients with systemic sclerosis and written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}